Multi-omics integration identifies serum FTL as a novel diagnostic biomarker for esophageal squamous cell carcinoma
5 affiliations
- 1Postdoctoral Research Station, Chaozhou People’s Hospital, Affiliated Chaozhou Hospital of Shantou University Medical College
- 2Department of Clinical Laboratory, Affiliated Chaozhou Hospital of Shantou University Medical College
- 3Department of Clinical Laboratory, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Sun Yat-Sen University Cancer Center
- 4School of Medical Technology, Guangdong Medical University
- 5Department of Gastroenterology, Chaozhou People’s Hospital, Affiliated Chaozhou Hospital of Shantou University Medical College
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is a common malignant tumor in China, with a poor five-year survival rate due to the lack of effective early diagnostic methods. This study aimed to identify potential non-invasive biomarkers and clarify their underlying mechanisms.
Methods: We employed an integrative approach combining serum proteomic profiling, bulk RNA sequencing, and single-cell RNA-seq (scRNA-seq) analyses. Quantitative proteomics was conducted on 15 serum samples of treatment-naive early-stage ESCC patients and 5 from healthy controls. Differentially expressed proteins (DEPs) were cross-referenced with differentially expressed genes (DEGs) from the GSE53624 dataset, and a diagnostic model was developed using LASSO regression. Cross-validation was performed using scRNA-seq data. The enzyme-linked immunosorbent assay (ELISA) was utilized to validate FTL in 155 serum samples from two centers. In silico FTL knockouts were conducted using scTenifoldKnk, followed by GO, KEGG, and PPI network analyses.
Results: Proteomic profiling identified a total of 129 DEPs. Intersection with GSE53624 DEGs yielded 8 overlapping genes, and a 6-biomarker (TF, CHAD, CSRP1, FCGR3A, RCN1, FTL) diagnostic model was built, with AUC 0.882–1.0 across validation cohorts. scRNA-seq intersection analysis identified FTL as the only overlapping DEG, exhibiting high expression levels in ESCC epithelial cells and macrophages. FTL demonstrated strong standalone diagnostic performance, with AUC values ranging from 0.872 to 0.970 across three GEO datasets. ELISA validation yielded an AUC of 0.75 (95% CI: 0.674–0.816) and 0.838 (95% CI: 0.751–0.905) for early-stage ESCC, surpassing the performance of CEA and SCCA. The combination of FTL with SCCA further enhanced discriminatory efficacy. Mechanistically, FTL was associated with altered immune cell infiltration, characterized by increased resting dendritic cells and M2 macrophages and decreased follicular helper T cells, as well as activation of the ferroptosis pathway. In silico FTL knockouts revealed DEGs enriched in stress and metabolic biological processes, extracellular vesicles (cellular component), transcriptional regulation (molecular function, CHOP-ATF3 complex), IL-17/TNF pathways, and lipid/ROS-related pathways. Protein-protein interaction hubs included FOS, ATF3, NFKBIA, and CXCL8, with FTL linked to NFE2L2, TFRC, and TXNRD1.
Conclusions: FTL represents a credible non-invasive serum diagnostic biomarker for ESCC. Computational analyses suggest it is a candidate molecule requiring further mechanistic and therapeutic investigation.
Related
- The ferroptosis-related LncRNA CASC9 reveals its potential as a diagnostic and prognostic biomarker in esophageal squamous cell carcinoma
- Multi-omics integration identifies PON2 as a prognostic biomarker and mediator of tumor microenvironment remodeling in gallbladder cancer
- Pan-cancer analysis identifies ANGPT4 as a potential prognostic biomarker associated with the tumor microenvironment in kidney renal clear cell carcinoma
- Integrated Transcriptomic and Network Analysis Identifies Diagnostic and Immune-Associated Hub Genes in Urothelial Carcinoma
- High-Resolution Esophageal Manometry in Mongolia: The First National Experience and Diagnostic Spectrum of Esophageal Motility Disorders
BibTeX
@article{chen2026multiomics,
title = {{Multi-omics integration identifies serum FTL as a novel diagnostic biomarker for esophageal squamous cell carcinoma}},
author = {Wei-Zhong Chen and Shu-Lin Chen and Run-Kun Han and Xiao-Ru Wu and Jia-Cong Liang and Mian-Tao Wu and Guang-Yu Sun and Hao Chen},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1935836},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1935836/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Multi-omics integration identifies serum FTL as a novel diagnostic biomarker for esophageal squamous cell carcinoma
AU - Wei-Zhong Chen
AU - Shu-Lin Chen
AU - Run-Kun Han
AU - Xiao-Ru Wu
AU - Jia-Cong Liang
AU - Mian-Tao Wu
AU - Guang-Yu Sun
AU - Hao Chen
PY - 2026
DA - 2026/10/28
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1935836
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1935836/full
AB - Background: Esophageal squamous cell carcinoma (ESCC) is a common malignant tumor in China, with a poor five-year survival rate due to the lack of effective early diagnostic methods. This study aimed to identify potential non-invasive biomarkers and clarify their underlying mechanisms. Methods: We employed an integrative approach combining serum proteomic profiling, bulk RNA sequencing, and single-cell RNA-seq (scRNA-seq) analyses. Quantitative proteomics was conducted on 15 serum samples of treatment-naive early-stage ESCC patients and 5 from healthy controls. Differentially expressed proteins (DEPs) were cross-referenced with differentially expressed genes (DEGs) from the GSE53624 dataset, and a diagnostic model was developed using LASSO regression. Cross-validation was performed using scRNA-seq data. The enzyme-linked immunosorbent assay (ELISA) was utilized to validate FTL in 155 serum samples from two centers. In silico FTL knockouts were conducted using scTenifoldKnk, followed by GO, KEGG, and PPI network analyses. Results: Proteomic profiling identified a total of 129 DEPs. Intersection with GSE53624 DEGs yielded 8 overlapping genes, and a 6-biomarker (TF, CHAD, CSRP1, FCGR3A, RCN1, FTL) diagnostic model was built, with AUC 0.882–1.0 across validation cohorts. scRNA-seq intersection analysis identified FTL as the only overlapping DEG, exhibiting high expression levels in ESCC epithelial cells and macrophages. FTL demonstrated strong standalone diagnostic performance, with AUC values ranging from 0.872 to 0.970 across three GEO datasets. ELISA validation yielded an AUC of 0.75 (95% CI: 0.674–0.816) and 0.838 (95% CI: 0.751–0.905) for early-stage ESCC, surpassing the performance of CEA and SCCA. The combination of FTL with SCCA further enhanced discriminatory efficacy. Mechanistically, FTL was associated with altered immune cell infiltration, characterized by increased resting dendritic cells and M2 macrophages and decreased follicular helper T cells, as well as activation of the ferroptosis pathway. In silico FTL knockouts revealed DEGs enriched in stress and metabolic biological processes, extracellular vesicles (cellular component), transcriptional regulation (molecular function, CHOP-ATF3 complex), IL-17/TNF pathways, and lipid/ROS-related pathways. Protein-protein interaction hubs included FOS, ATF3, NFKBIA, and CXCL8, with FTL linked to NFE2L2, TFRC, and TXNRD1. Conclusions: FTL represents a credible non-invasive serum diagnostic biomarker for ESCC. Computational analyses suggest it is a candidate molecule requiring further mechanistic and therapeutic investigation.
SN - 1664-3224
ER -